Sharp Therapeutics Announces C$1.365M Non-Brokered Private Placement and Shifts Focus to New Lead Drug Candidate

Details of the Non-Brokered Private Placement

On July 15, 2026, Sharp Therapeutics announced a non-brokered private placement to raise gross proceeds up to C$1,365,000 by issuing common shares at a minimum price of C$0.91 each. The offering is anticipated to close in Q3 2026, pending approval from the TSX Venture Exchange.

This non-brokered structure means no underwriters or agents are involved, a common approach for smaller companies to minimize issuance expenses. Net proceeds are designated for general working capital, though the company has not specified how these funds will be allocated across operational needs.

Insider Investment and Related-Party Transaction Disclosure

A significant aspect of the placement is the participation of Newlin Investment Company 1, LLC, wholly owned by Sharp’s Chairman and director, William R. Newlin. The entity intends to subscribe for about US$200,000 on the same terms as other investors. Under Canadian securities laws, this constitutes a related-party transaction per Multilateral Instrument 61-101.

Sharp Therapeutics has stated it is exempt from requiring a formal valuation or minority shareholder approval for this transaction, relying on sections 5.5(a) and 5.7(1)(a) of MI 61-101, since the value of securities issued and consideration does not exceed 25% of the company’s market capitalization. Insider participation often signals confidence in the company’s prospects, though investors should independently evaluate the transaction.

Hold Period, Regulatory Approvals, and U.S. Securities Compliance

All shares issued in this offering will be subject to a mandatory four-month hold period from issuance date, restricting trading during this timeframe as per Canadian securities regulations. The closing of the offering remains contingent on TSX Venture Exchange approval, with no guarantees on timing or outcome.

The announcement also highlights that the securities are not registered under the U.S. Securities Act of 1933, meaning they cannot be offered or sold in the U.S. without registration or an exemption. The release explicitly states it is not for distribution via U.S. news wire services or within the United States, adhering to cross-border regulatory requirements for TSXV-listed companies with U.S. investors.

Strategic Shift to an Alternative Lead Drug Candidate

A major strategic update reveals Sharp Therapeutics’ decision to advance a different lead candidate within its primary development program. The company did not disclose the candidate’s name or detailed scientific rationale but indicated this shift will delay certain capital needs by approximately six to twelve months.

This adjustment reflects a significant realignment of the company’s scientific and strategic priorities. It also reduces near-term capital requirements compared to prior financing plans. While specific revised timelines were not provided, this pivot may impact expectations regarding program milestones for investors.

Ending of STX Partners Financing Agreement and US$10 Million Commitment

Following the lead candidate update and reduced capital needs, Sharp and STX Partners mutually agreed to terminate the previously announced letter agreement for a proposed financing of about US$10,000,000, including the associated conditional share purchase commitment.

The termination is described as mutual and a direct result of the changed capital requirements rather than any relationship issues. No termination fees, penalties, or further obligations were disclosed. This cancellation marks a significant change in Sharp’s capital strategy, which now centers on the smaller non-brokered private placement and operational savings from the program shift.

Sharp Therapeutics’ Discovery Platform and Preclinical Focus

Sharp Therapeutics is a preclinical-stage company developing "first-choice" small-molecule therapeutics for genetic diseases. Its discovery platform integrates novel high-throughput screening with computationally optimized compound libraries, targeting cellular trafficking defects and allosteric protein activation.

The platform aims to create small molecules that restore mutated protein activity, offering potential oral treatments for genetic disorders that may be more convenient than gene therapies or biologics. Headquartered in Pittsburgh, Pennsylvania, and Toronto, Ontario, Sharp has yet to enter human clinical trials, with all candidates currently in early development stages.

Implications of Reduced Near-Term Financing Needs on Capital Strategy

The combination of the lead candidate pivot and termination of the STX agreement significantly alters Sharp’s previously communicated capital outlook. Management’s assertion that capital needs are deferred by six to twelve months suggests existing and near-term resources, including proceeds from the private placement, may be adequate to support operations during this phase.

The offering’s size of up to C$1,365,000 is substantially less than the US$10,000,000 previously contemplated, underscoring the operational update’s impact on financing priorities. The company has not provided detailed guidance on cash runway or projected expenses post-offering, so investors should monitor future disclosures for financial clarity.

Dual Listing and Market Context for Preclinical Biotech Firms

Sharp Therapeutics trades on the TSX Venture Exchange under SHRX and on the OTCQB in the U.S. as SHRXF, enabling access for Canadian and American investors. However, securities from the current private placement are not available to U.S. investors without applicable exemptions.

Preclinical biotech companies on the TSXV often face capital constraints while advancing toward clinical milestones, making private placements a routine but closely observed corporate activity. The immediate market reaction to this announcement was not evident at the time of writing. Investors will likely watch how the market responds to the new financing, strategic program pivot, and termination of the larger STX financing arrangement.

Forward-Looking Statements and Regulatory Disclaimers

The announcement includes standard forward-looking information disclaimers required by Canadian securities laws. Sharp Therapeutics cautions that projections regarding the offering’s closing, capital requirement delays, and development platform are subject to risks and uncertainties that could cause actual results to differ materially.

The TSX Venture Exchange and its Regulation Services Provider disclaim responsibility for the release’s adequacy or accuracy. Sharp disclaims responsibility for forward-looking information beyond the release date except as required by law. Investors are encouraged to review all regulatory filings, including material change reports and continuous disclosure documents on SEDAR+, for comprehensive insights into the company’s financial and operational status.